Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

Core Insights - Resmed has launched its FDA-cleared home sleep apnea test, NightOwl™, across the United States, aimed at simplifying the diagnosis of obstructive sleep apnea (OSA) for healthcare providers and patients [1][5]. Company Overview - Resmed is a leading health technology company focused on sleep, breathing, and home care, committed to innovative technology that empowers individuals to live healthier lives [5]. - The company envisions a world where everyone can achieve their full potential through better sleep and breathing, with care delivered at home [5]. Product Features - NightOwl is a disposable home sleep apnea test device that records up to 10 nights of sleep data, capturing variability and providing clinicians with a comprehensive view of sleep patterns [3][7]. - The device uses peripheral arterial tonometry technology to measure blood flow changes, oxygen saturation, and pulse rate, demonstrating high accuracy in detecting OSA [4][7]. - NightOwl integrates with Resmed's myAir™ app, offering step-by-step guidance for users throughout the testing process [7]. Market Context - OSA affects nearly one billion people globally, with approximately 80% of cases remaining undiagnosed and untreated, highlighting the need for accessible diagnostic options [2]. - A study indicates that treating OSA with CPAP therapy can significantly reduce the risk of death, emphasizing the importance of effective diagnosis [2][3].